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Abstract
Drug-resistant HIV complicates management of HIV infection. Although an estimated 14% of all HIV-positive
persons pass through a prison or jail in the United States each year, little is known about the overall prevalence
of antiretroviral (ARV) resistance in incarcerated persons. All genotypic sequence data on HIV-positive prisoners
in the North Carolina (NC) Department of Corrections (DOC) were obtained from LabCorp. Screening for major
resistance mutations in protease (PI) and reverse transcriptase (NRTI and NNRTI) was done using Genosure and
the Stanford HIV Database. For subjects with multiple genotype reports, each mutation was counted only once
and considered present on all subsequent genotypes. Between October 2006 and February 2010, the NC DOC
incarcerated 1,911 HIV + individuals of whom 19.2% (n = 367) had at least one genotype performed. The overall
prevalence of a major resistance mutation was 28.3% (95% CI 23.7, 33.0). Among prisoners ever exposed to an
ARV during incarceration (n = 329) prevalence of a major resistance mutation was 29.8% (95% CI 24.9, 34.7);
resistance by class was 20.4% (95% CI 16.0, 24.7) for NRTIs, 19.8% (95% CI 15.5, 24.1) for NNRTIs, and 8.8% (95%
CI 5.8,11.9) for PIs. Single class drug resistance was most prevalent at 14.2% (10.2,17.7) followed by dual 12.5%
(I8.9,16.0) and triple class 3.3% (1.4,5.3) resistance. The three most prevalent mutations were K103N 15.8% (12.0,
20.2), M184V 14.3% (10.7,18.5), and M41L 4.9% (2.8,7.8). In the NC DOC ARV resistance prevalence, dual and
triple class drug resistance was moderate over the study period. Resistance to PIs was lower than NNRTIs and
NRTIs, likely reflecting higher usage of these two classes or a lower barrier to resistance.
Introduction
In the United States, an estimated 14% of all HIV-positivepersons pass through a prison or jail each year.1 While in-
carcerated, antiretroviral (ARV) adherence among U.S. pris-
oners is reported to be high.2,3 However, recidivism is
common and cycling in and out of prison can be associated
with treatment interruptions and reduced adherence to ARV
medications.4–6 Suboptimal adherence promotes ARV resis-
tance, reduces the availability of effective therapies, and re-
sults in more complex, expensive treatment options that may
be less tolerable.
Determining the prevalence of ARV resistance among ARV
therapy-exposed patients is challenging. Drug resistance
testing is generally feasible clinically when plasma HIV RNA
is > 500 c/ml and resistance testing may not be performed in
all cases of ARV failure or before wild-type virus overgrows
resistant strains following ARV cessation. Comparing the
prevalence estimates of HIV drug resistance across published
studies is challenging as results are dependent on several
variables including the population under study (chronically
infected vs. treatment naive), the definition of resistance, the
denominator used (all patients on treatment vs. only those
with genotypes), and the time period under study. Reported
prevalence estimates of HIV resistance among patients on
ARV treatment can range from as little as 17% to an alarm-
ingly high value of 76–81%.7–12
Although the development of drug-resistant virus has im-
portant implications for treatment of HIV infection, little is
known about the overall prevalence of ARV resistance among
incarcerated persons, a population that carries a dispropor-
tionate burden of HIV. To date, there have been only five
studies examining ARV resistance among prisoners—two in
the United States13,14 and three in Europe.15–17 Of the two
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studies conducted in the United States,13 one focused on 67
seroconverters during incarceration and restricted surveil-
lance to only four major mutations.14 The second study
surveyed only 25 ARV treatment-naive prisoners.13 The
generalizability of the two studies conducted in the United
States13 is limited by their small sample sizes and by their
focus on HIV-infected ARV treatment-naive prisoners.
The North Carolina (NC) state prison system incarcerates
approximately 40,000 prisoners annually18 with an estimated
HIV prevalence of 2.1%, the fifth highest prevalence of HIV
among all U.S. state prisons.19 Although resistance testing is
conducted in the NC prison system as a component of routine
HIV care, as in other state prison systems, the prevalence of
ARV-resistant variants among the population of HIV-positive
prisoners has not been well characterized. To broaden our
current understanding of HIV resistance among prisoners, we
sought to determine the ARV resistance burden among a co-
hort of HIV-positive incarcerated men and women receiving
HIV care in the North Carolina Department of Correction, a
large prison system in the Southeast United States.13
Materials and Methods
Study population
For the period October 2006 to February 2010, we obtained
the following data for all HIV-positive inmates from all 87
prison facilities within the NC Department of Correction (NC
DOC) prison system: demographic characteristics (age, race,
gender), dates of incarceration, recidivism status, an indicator
of any ARV use in prison (based on electronic prescription
data), and among prisoners who received a genotype test for
drug resistance to HIV-1, the nucleoside sequencing result
and corresponding plasma viral load within 120 days of
genotype testing.
Within the NC DOC, four Infectious Disease (ID) clinics
provide HIV care to all HIV-positive inmates housed in the 87
prison facilities. Because inmates may be moved between
different prison facilities, they might start HIV care in one ID
clinic but later be seen in another of the ID clinics. As all four
clinics are staffed by Infectious Disease clinicians, and there is
some overlap of clinicians between clinics, HIV care is very
centralized and standardized and there is little in the way of
unequal access to genotypes. Only the ID trained clinicians
providing HIV care at the four clinics order genotype tests for
routine clinical care.
ARV resistance testing
Genotype tests were obtained as part of routine clinical care
and were performed by LabCorp (Research Triangle Park,
NC) using HIV GenoSure. Nucleotide sequences were
submitted to the Stanford University HIV Drug Resistance
Database (HIVdb) via Sierra, the Stanford Algorithm web
service.20 Mutations were categorized as major mutations if
identified in the HIVdb as ‘‘associated with higher levels of
phenotypic resistance or clinical evidence for reduced viro-
logic response.’’21
Antiretroviral treatment history
Data were not available describing prisoners’ use of ARVs
prior to their incarceration and for recidivists between periods
of incarceration. Data describing in-prison use of ARVs were
limited to an indicator variable differentiating prisoners never
and ever prescribed an ARV medication during their incar-
ceration. For simplicity, we refer to these groups as ever
prescribed an ARV during incarceration (EPADI) and never
prescribed an ARV during incarceration (NPADI).
Statistical analysis
Prisoners with genotypes vs. without genotypes. In bi-
variate analyses, we compared sex, race, recidivism, and ARV
experience (EPADI vs. NPADI) by genotype testing status
using tests of chi-square.
Analyses of resistance prevalence. For prisoners with
multiple genotype reports, resistant mutations were consid-
ered present for all subsequent genotype reports; mutations
appearing repeatedly across multiple genotype reports for the
same individual were counted only once in our prevalence
estimates. All tests for statistical significance were conducted
at the level of a = 0.05, and 95% confidence intervals were
calculated for all prevalence point estimates.
Prisoners ever prescribed an ARV during incarceration
(EPADI) with ‡ 1 genotype. Among prisoners with an in-
dication of an ARV prescription in prison, we compared the
proportion of prisoners across categories within the variables
sex, race, and recidivism status. We then obtained prevalence
estimates for individual resistance mutations over four
time periods (October 2006–February 2010, October 2006–
December 2007, January 2008–December 2008, and January
2009–February 2010) and by number of ARV-resistant medi-
cation classes (no-, single-, dual-, and triple-ARV class resis-
tance) across the entire study period.
Prisoners never prescribed an ARV during incarceration
(NPADI) with ‡ 1 genotype. Among prisoners with no in-
dication of an ARV prescription during their incarceration, we
estimated the prevalence of each detected mutation for the
entire study period, October 2006–February 2010.
This study was approved by the Biomedical Institutional
Review Board of the University of North Carolina at Chapel
Hill and by the Human Subjects Review Committee of the
North Carolina Department of Corrections
Results
Sample characteristics
Between October 2006 to February 2010, the NC DOC in-
carcerated 1,911 known HIV-positive persons of whom 19.2%
(n = 367) had at least one genotype performed. Of the 367
prisoners with genotypes most were male (85.8%), black
(79.3%), experienced with ARV treatment in prison (89.4%),
and recidivists (68.4%) at the time of their first incarceration
during the study period. Twenty-eight percent had multiple
incarcerations during the study period (Table 1). The median
plasma HIV RNA level obtained within 120 days prior to
genotype testing was 4.41 log10 (IQR: 3.78, 4.87). A small
number (n = 36) of prisoners had multiple genotypes; 28 in-
mates had two, seven inmates had three, and one inmate had
four genotypes.
Comparing the characteristics of prisoners with genotypes
to those without a genotype, we found no statistically sig-
nificant differences by race, gender, and recidivism rate
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(Table 1). However, prisoners with genotypes were modestly
younger than those without genotypes (mean age 38.4 years
vs. 40.0 years, p < 0.05) and were more likely to have been
prescribed an ARV in prison (Table 1) ( p < 0.05).
The characteristics of the prisoners ever prescribed an an-
tiretroviral during incarceration with genotypes (n = 329)
were similar to the overall HIV-infected prison population,
with most being male (85.4%), black (80.2%), and recidivists
(69.3%) (Table 2).
ARV resistance prevalence
All prisoners with genotypes. The overall prevalence of a
major resistance mutation was 28.3%, (95% CI 23.7, 33.0).
Resistance by class was 18.8% (95% CI 14.8, 22.8) for nucleo-
side reverse transcriptase inhibitors (NRTIs), 19.1% (95% CI
15.1, 23.1) for nonnucleoside reverse transcriptase inhibitors
(NNRTIs), and 7.9% (95% CI 5.1, 10.7) for protease inhibitors
(PIs).
ARV resistance among prisoners EPADI. Overall prev-
alence of a major resistance mutation was 29.8% (95% CI 24.9,
34.7). Resistance by class was 20.4% (95% CI 16.0, 24.7) for
NRTIs, 19.8% ( 95% CI 15.5, 24.1) for NNRTIs, and 8.8% (95%
CI 5.8,11.9) for PIs (Fig. 1). Resistance to specific ARV drugs is
shown in Fig. 1. Comparing 2007 to 2009, prevalent and class
specific resistance declined (Fig. 2). The three most prevalent
mutations were K103N 15.8% (95% CI 12.0, 20.2), M184V
14.3% (95% CI 10.7,18.5), and M41L 4.9% (95% CI 2.8,7.8)
(Table 3). K103N and M184V remained the two most preva-
lent mutations for each time period studied. Nineteen patients
Table 1. Genotype Testing Among HIV-Positive
Prisoners in the North Carolina Department







N % N % p value
Sex
Female 305 16.0 52 14.2 0.30
Male 1606 315
Race
Black 1527 79.9 291 79.3 0.74
Nonblack 384 76
Incarceration
First incarcerationa 494 25.9 93 25.3 0.97
Reincarceration 1296 67.8 251 68.4
Otherb 121 23
ARV treatment in prison
Ever 1445 75.6 329 89.6 < 0.0001
Never 466 38
aFirst incarceration during study period.
bOther includes safekeeper, returned from parole, or awaiting
sentencing.
ARV, antiretroviral.
Table 2. Demographics of HIV-Positive Prisoners ever
Exposed to an ARV During Incarceration (EPADI)
with Genotype Testing in North Carolina Department
of Corrections, October 2006 - February 2010
N %
Study population 329 100 p value
Sex p < 0.05
Female 48 14.6
Male 281 85.4
Race p < 0.05
Black 264 80.2
Nonblacka 65 19.8
Incarceration p < 0.05
First Incarecrationa 79 24.0
Reincarecration 228 69.3
Otherb 22 6.7
Age 329 37.9 IQR (31.5–44.2)
Viral load (log10) 292 4.45 IQR (3.75–4.88)
aFirst incarceration during study period.
bOther includes safekeeper, returned from parole, or awaiting
sentencing.
FIG. 1. Proportion of HIV-positive prisoners ever pre-
scribed an ARV during incarceration with genotype testing
and ARV medication resistance in the North Carolina De-
partment of Corrections, October 2006 - February 2010.
FIG. 2. Prevalent and antiretroviral class-specific resistance
among HIV-infected persons in the North Carolina prison
system (95% CI).
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had a single mutation with K103N and eight patients had a
single mutation with M184V.
Single class drug resistance was most prevalent at 14.0%
(95% CI 10.2,17.7) followed by dual 12.5% (95% CI 8.9,16.0)
and triple class 3.3% (95% CI 1.4,5.3) resistance (Table 3).
ARV resistance among prisoners NPADI. Among the 367
patients with genotypes, 38 had no known history of ARV
treatment in prison. Of these, 15.8% (6/38) had a major mu-
tation (one patient: K103N and M184V; four patients: K103N
only; and one patient: M41L only) (Table 4).
Discussion
This is the first study to characterize the prevalence of ARV
resistance among prisoners with chronic HIV infection in the
United States.13 Our analysis included all prison facilities in
NC, includes a contemporary time period, and is the largest
study of ARV resistance among prisoners in the United
States.13 Between 2006 and 2010, ARV resistance prevalence,
including dual and triple class drug resistance, was found to
be low among HIV-positive persons incarcerated in the North
Carolina Department of Corrections.
The prevalence of at least one ARV resistance mutation
(29.8%) among prisoners ever prescribed an antiretroviral
during incarceration (EPADI) in NC is slightly lower but in
keeping with the reported prevalence in prisons in Spain
(38.6%).15 This prevalence estimate is also lower than the re-
ported prevalence estimates (37–88%) from studies among the
nonincarcerated HIV-positive population receiving ARV
therapy.7–12 However, we emphasize that comparing preva-
lence estimates across studies is complex due to differences in
resistance definitions, time periods under study, analytic
methods, and study populations. In our cohort, the dates of
ARV treatment exposure were not obtainable and sufficient
time may have elapsed between treatment discontinuation
and obtaining prisoners’ genotypes to allow for the emer-
gence of wild-type virus. We are further limited by lack of
data on medication adherence, and poor or nonadherence
could have influenced our prevalence estimates. In keeping
with other studies, ARV resistance prevalence declined from
the earliest to the most recent time period.8,10,22 This could be
due to the availability of more effective, potent, tolerable
therapy and the availability of potent combination therapy
with activity against resistant variants including a new agent
in a novel class (raltegravir).
Among prisoners ever prescribed an antiretroviral during
incarceration, ARV class-specific resistance was highest for
the NNRTIs and NRTIs. In line with the class-specific resis-
tance, the most prevalent detected mutations were M184V
and K103N. PI resistance was the lowest. These results are in
agreement with the study conducted in Spanish prisoners15
and might be explained by the lower genetic barrier to resis-
tance of NRTIs and NNRTIs. Our results could also be a re-
flection of increased use of NRTIs and NNRTIs, due to their
tolerability and, with fixed dose combinations, greater ease
of administration. Reassuringly, dual and triple class drug
resistance was low. The prevalence estimates for triple class
resistance (defined as at least one mutation to the NRTI,
NNRTI, and PI drug class) among ARV treatment-experienced
Table 3. Frequency of Major ARV Mutations Among HIV-Positive Prisoners ever Exposed
to an ARV During Incarceration (EPADI) with Genotype Testing in North Carolina
Department of Corrections, October 2006 - February 2010 (n = 329)
NNRTI N % (95% CI) NRTI N % (95% CI) PI N % (95% CI)
K103N 52 15.81 (12.0,20.2) M184V 47 14.29 (10.7,18.5) I50V 12 3.65 (1.9,6.3)
Y181C 9 2.74 (1.3,5.1) M41L 16 4.86 (2.8,7.8) L90M 7 2.13 (0.9,4.3)
G190S 4 1.22 (0.3,3.1) K65R 8 2.43 (1.1,4.7) I54V 6 1.82 (0.7,3.9)
K101E 4 1.22 (0.3,3.1) M184I 7 2.13 (0.9,4.3) M46I 6 1.82 (0.7,3.9)
K103S 4 1.22 (0.3,3.1) L74V 6 1.82 (0.8,3.9) I84V 5 1.52 (0.5,3.5)
G190A 3 0.91 (0.2,2.6) L74I 5 1.52 (0.5,3.5) V82A 5 1.52 (0.5,3.5)
K101P 3 0.91 (0.2,2.6) T215F 5 1.52 (0.5,3.5) N88D 4 1.22 (0.3,3.1)
K238T 3 0.91 (0.2,2.6) T215Y 5 1.52 (0.5,3.5) D30N 3 0.91 (0.2,2.6)
L100I 3 0.91 (0.2,2.6) T69ADNT 3 0.91 (0.2,2.6) I54L 2 0.61 (0.1,2.2)
Y188L 3 0.91 (0.2,2.6) T69NT 2 0.61 (0.1,2.2) V32I 2 0.61 (0.1,2.2)
V106M 2 0.61 (0.1,2.2)
Mutations with only a single occurrence were M230L, V106A, T69AT, V75T, Y115F, F53L, G48V, G73S, G73T, I47V, I50L, L23I, M46L, and
V82T.
NNRTI, nonnucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; PI, protease inhibitors.
Table 4. Number of ARV Classes with a Major Mutation Among HIV-Positive Prisoners ever Exposed
to an Antiretroviral During Incarceration with Genotype Testing in North Carolina
Department of Corrections, October 2006 - February 2010
No mutations NRTI NNRTI PI NRTI/NNRTI NRTI/PI NNRTI/PI Three classes
N 231 16 22 8 31 9 1 11
% 70.2 4.9 6.7 2.4 9.4 2.7 0.3 3.3
95% CI 65.3, 75.2 2.5, 7.2 4.0, 9.4 0.8, 4.1 6.3, 12.6 1.0, 4.5 0, 0.9 1.4, 5.3
NNRTI, nonnucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; PI, protease inhibitors.
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nonincarcerated North Carolinians has been reported as 8%
contrasted with the 3.3% observed in our study.23
Among prisoners with no indication of ARV treatment
experience during incarceration, we detected a higher (13.2%)
prevalence of the K103 N mutation in comparison to preva-
lence estimates among treatment-naive populations from
both correctional and noncorrectional settings.13,15,16,24
However, the relatively high prevalence of K103 mutations in
our study as compared to others may simply reflect unmea-
sured ARV exposure immediately prior to incarceration; the
estimate should also be interpreted with caution due to the
small sample size. Although small, our sample of prisoners
with no indication of ARV treatment in prison is similar in size
to the naive subjects in other prison studies (Spanish n = 43;
Italian n = 16; Massachusetts n = 25).13,15,16 Furthermore, our
overall prevalence estimate for ARV resistance in this group
of prisoners is similar to that of the Massachusetts cohort.13
Centralization of HIV care in the NC DOC, limited to only
four ID clinics for the entire state and staffed by a dedicated
group of ID trained clinicians, is a study strength as it likely
results in similar access to genotype testing for all HIV-posi-
tive inmates. Therefore, our study population likely is a good
representation of all HIV-positive NC state prisoners in the
study period.
In addition to the limitations we have discussed so far, our
results are limited by lack of information on specific ARV
treatment regimens at the time of genotype testing, prior
ARV treatment history, and adherence to prescribed ARV
treatments. Second, use of clinical genotype data may not
fully capture the prevalence of resistance mutations in the
population. We note that the denominator for our prevalence
estimates was based on the number of prisoners with
genotypes—a population representing less than 20% of all
known HIV-infected NC prisoners incarcerated during the
study period. However, the proportion of prisoners with
genotypes in our study is similar to that of other published
reports.16 Because resistant testing can be conducted only
when viral load is > 500 HIV RNA c/ml, it is possible that
our results underestimate the true prevalence of resistance in
the NC prison population because prisoners with viral loads
between 40 and 500 HIV RNA c/ml may not have been
genotyped.
This study provides important surveillance data on a
population that can be difficult to access (both in prison and in
the community) and one that may have high rates of treat-
ment interruptions given the often chaotic lives of people who
cycle in out of the criminal justice system. The low estimates of
ARV resistance prevalence is very encouraging. However,
given the low number of resistance tests performed during the
study period we believe there is an urgent need to more
rapidly and rigorously implement current guidelines for ge-
notype testing in this group.25 In addition, we recommend
that all correctional facilities be included in antiretroviral re-
sistance surveillance programs at the state and national levels.
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JC, and Grupo de Estudio REPRICOVA. [Primary HIV drug
resistance in a prison population. REPRICOVA-2 Study].
[Article in Spanish.] Enferm Infecc Microbiol Clin 2004;22(1):
29–31.
18. Rosu R: Research Bulletin. North Carolina Department
of Correction. Issue No. 52. March 4, 2009. Available at
http://randp.doc.state.nc.us/scripts/broker.exe?_SERVICE =
default&_PROGRAM = sasjobs.Research.sas&_DEBUG = 0.
19. Maruschak LM and Beavers R: HIV in Prisons, 2007–08.
Bureau of Justice Statistics. December 2009, NCJ 228307.
Available at bjs.ojp.usdoj.gov/content/pub/pdf/rpr94.pdf.
20. http://hivdb.stanford.edu/pages/webservices/.
21. HIV Drug Resistance Mutations by Drug Class (November
6, 2009). Available at http://hivdb.stanford.edu/pages/
download/resistanceMutations handout.pdf.
22. Aldous J, Jain S, Sun S, et al.: Decreasing prevalence of drug
resistance mutations over a 7 year period in the CFAR net-
work of integrated clinical systems. 17th Conference on
Retroviruses and Opportunistic Infections, February 2010.
Paper #585.
23. Napravnik S, Keys JR, and Quinlivan EB: Triple class anti-
retroviral drug resistance: Risk and predictors among HIV-1
infected patients. AIDS 2007;21:825–834.
24. Hurt CB, McCoy SI, Kuruc J, et al.: Transmitted drug
resistance among acute and recent HIV infections in
North Carolina, 1998 to 2007. Anitviral Ther 2009;14(5);
673–678.
25. Panel on Antiretroviral Guidelines for Adults and Adoles-
cents. Guidelines for the use of antiretroviral agents in HIV-
1-infected adults and adolescents. Department of Health and
Human Services. January 10, 2011; 1–166. Available at
www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL




130 Mason Farm Road
Chapel Hill, North Carolina 27599
E-mail: menez001@med.unc.edu
ARV RESISTANCE AMONG HIV-POSITIVE PRISONERS 141
